K, Okawa M, Shibui K, Kudo Y, Doi Y, Minowa M, Ogihara R: Sleep loss and daytime sleepiness in the basic adult population of Japan. Psychiatry Res 2000, 93(1):11. 34. Ramakrishnan K, Scheid DC: Remedy choices for insomnia. Am Fam Physician 2007, 76(4):51726. 35. Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M: The efficacy and safety of drug remedies for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007, 22(9):1335350. 36. Doghramji K: Melatonin and its receptors: a new class of sleeppromoting agents. J Clin Sleep Med 2007, 3(five Suppl):S17 23. 37. Nowak JZ, Zawilska JB: Melatonin and its physiological and therapeutic properties. Pharm Planet Sci 1998, 20(1):187. 38. Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T: Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in individuals with benign prostatic hyperplasia. Int J Urol 2006, 13(1):150.doi:ten.1186/1471-2490-13-30 Cite this short article as: Kawahara et al.: Ramelteon combined with an 1blocker decreases nocturia in men with benign prostatic hyperplasia. BMC Urology 2013 13:30.Submit your subsequent manuscript to BioMed Central and take full advantage of:Hassle-free on line submission Thorough peer assessment No space constraints or colour figure charges Immediate publication on acceptance Inclusion in PubMed, CAS, Scopus and Google Scholar Investigation which can be freely accessible for redistributionSubmit your manuscript at www.biomedcentral/submit
Europe PMC Funders GroupAuthor Manuscript Trends Genet. Author manuscript; readily available in PMC 2014 January 21.Published in final edited kind as: Trends Genet. 2013 September ; 29(9): 51320. doi:10.1016/j.tig.2013.06.007.Europe PMC Funders Author Manuscripts Europe PMC Funders Author ManuscriptsTelomerase at the intersection of cancer and agingBruno Bernardes de Jesus1 and Maria A. Blasco1,* 1Telomeres and Telomerase Group, Molecular Oncology System, Spanish National Cancer Study Centre (CNIO), Melchor Fern dez Almagro three, Madrid, E-28029, SpainAbstractAlthough cancer and aging happen to be studied as independent ailments, mounting evidence suggest that cancer is an aging-associated disease and that cancer and aging share numerous molecular pathways.Surzebiclimab web In specific, recent research validated telomerase activation as a prospective therapeutic target for age-related illnesses, and at the very same time, abnormal telomerase expression and telomerase mutations have been related with quite a few distinct forms of human tumors.IL-31 MedChemExpress Right here, we revisit the connection of telomerase to cancer and aging in light of recent findings supporting a part for telomerase not merely in telomere elongation, but additionally in metabolic fitness and Wnt activation.PMID:24423657 Understanding the physiological influence of telomerase regulation is fundamental thinking about the therapeutic strategies which are becoming created involving telomerase modulation.Keyword phrases Telomerase; aging; cancerTelomerase defects may well cause aging and cancerTelomeres are repetitive DNA sequences at chromosome ends which are bound by a protective protein complicated referred to as shelterin, which prevents them from eliciting a DNA harm response (DDR) 1, 2. Seminal research have shown that telomeres shorten with each cell division due in component for the end-replication difficulty, an inability of your DNA replication machinery to totally replicate DNA ends 3-6. This really is paralleled by the silencing of telomerase, a reverse-transcriptase accountable f.
